company background image
ABBV logo

AbbVie NYSE:ABBV Stock Report

Last Price

US$182.10

Market Cap

US$319.3b

7D

2.6%

1Y

15.3%

Updated

28 Mar, 2024

Data

Company Financials +

Narratives

Beta

Narratives bring a range of perspectives from our community.

AbbVie Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$182.10
52 Week HighUS$182.89
52 Week LowUS$130.96
Beta0.56
1 Month Change1.74%
3 Month Change17.51%
1 Year Change15.31%
3 Year Change67.80%
5 Year Change119.90%
Change since IPO420.29%

Recent News & Updates

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

Mar 08

Recent updates

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

Mar 08

AbbVie: Things Are Getting Clearer

Feb 05

AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)

Jan 30

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

Jan 05
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

AbbVie: Time To Lock In Gains (Rating Downgrade)

Jan 03

AbbVie Vs. GSK: Dual Dominance In Pharma

Dec 23

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Dec 12
AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

Nov 29

AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

Nov 28
AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

Nov 21

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

Oct 30
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results

Oct 30

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans

Oct 23

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

Oct 16

AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

Sep 25
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths

Sep 15

AbbVie (NYSE:ABBV) Seems To Use Debt Quite Sensibly

Sep 07
AbbVie (NYSE:ABBV) Seems To Use Debt Quite Sensibly

Shareholder Returns

ABBVUS BiotechsUS Market
7D2.6%0.9%0.2%
1Y15.3%11.0%28.1%

Return vs Industry: ABBV exceeded the US Biotechs industry which returned 11% over the past year.

Return vs Market: ABBV underperformed the US Market which returned 28.1% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement2.1%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ABBV has not had significant price volatility in the past 3 months.

Volatility Over Time: ABBV's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201250,000Rick Gonzalezhttps://www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market capUS$319.34b
Earnings (TTM)US$4.82b
Revenue (TTM)US$54.32b

66.9x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABBV income statement (TTM)
RevenueUS$54.32b
Cost of RevenueUS$16.73b
Gross ProfitUS$37.59b
Other ExpensesUS$32.77b
EarningsUS$4.82b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.72
Gross Margin69.21%
Net Profit Margin8.87%
Debt/Equity Ratio573.6%

How did ABBV perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

220%

Payout Ratio

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks
When do you need to buy ABBV by to receive an upcoming dividend?
AbbVie dividend dates
Ex Dividend DateApr 12 2024
Dividend Pay DateMay 15 2024
Days until Ex dividend14 days
Days until Dividend pay date47 days

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.